Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Politics : Formerly About Advanced Micro Devices -- Ignore unavailable to you. Want to Upgrade?

To: longnshort who wrote (356586)	10/31/2007 12:02:19 PM
From: combjelly	Respond to of 1573257

"The British government’s National Statistics Web site lists prostate cancer survival from 1999 to 2004 at 74.4 percent. " And you have yet a different set of numbers from Harris. Who has come up with two sets of numbers on his own. I found this interesting. CONCLUSION: Although 5-year survival is a valid measure for comparing cancer therapies in a randomized trial, our analysis shows that changes in 5-year survival over time bear little relationship to changes in cancer mortality. Instead, they appear primarily related to changing patterns of diagnosis. JAMA. 2000. ncbi.nlm.nih.gov In the particular case of prostate cancer, in Britain screening isn't done at the same rate as in the US. However, they are increasing screening and their survival rate has been increasing as a result. So it doesn't seem to be a treatment issue, but an issue of catching it early. When they get to the point of PSA screening being done at malls like I have seen here, no doubt their 5 year rate will be comparable.